Araştırma Makalesi

MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT

Cilt: 47 Sayı: 1 20 Ocak 2023
PDF İndir
EN TR

MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT

Öz

Objective: The article is included formulation studies and in vitro evaluation of orally dispersible Rasagiline mesylate (RM) orodispersible films (ODFs) for non-oral treatment of Parkinson's Disease. RM undergoes extensive hepatic biotransformation and is a highly selective and irreversible MAO-B inhibitor. It is metabolized in the liver and has an oral bioavailability of approximately 36% and a half-life of 3 hours. These properties suggest that RM may be an excellent candidate for buccal drug delivery.
Material and Method: ODFs of RM were prepared using PEO by the solvent casting method. While evaluating these formulations, parameters such as appearance, weight homogeneity, thickness, surface pH, drug content, swelling ratio, tensile strength, mucoadhesion, in vitro drug release studies and also stability were considered.
Result and Discussion: Obtained results show that ODFs are an effective and viable approach for RM delivery and may be a new alternative to existing oral delivery systems for Parkinson's treatment.

Anahtar Kelimeler

Proje Numarası

219S545

Kaynakça

  1. 1. Pfeiffer RF.(2016). Non-motor symptoms in Parkinson’s disease. Park Relat Disord 22: S119–S122. [CrossRef]
  2. 2. Himanshu, Bhaskar R, Sharma N, Mehta M, Singh A, Yashwant, Yadav NS, Khatik GL, Verma S. (2017). Development and evaluation of buccoadhesive film of ropinirole hydrochloride for the treatment of Parkinson’s disease. Int J Drug Deliv Technol 7: 106–112. [CrossRef]
  3. 3. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G.( 2000). Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: A double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23: 324–330 [CrossRef]
  4. 4. Bukka R, Prakasam K, Patel CD. (2010). Preparation and Evaluation of Intraoral Drug Delivery System for Rasagiline mesylate. Int J Pharm Sci Drug Res 2: 294–301. [CrossRef]
  5. 5. Hoffmann EM, Breitenbach A, Breitkreutz J.( 2011). Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv 8: 299–316. [CrossRef]
  6. 6. Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. (2016). Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharm J 24: 537–546. [CrossRef]
  7. 7. Ravi PR, Aditya N, Cherian L, Patil S.(2013). LC Method for Determination of Rasagiline Mesylate in Different Plasma Matrices and its Application to Oral Pharmacokinetic Study in Rabbits. J Chromatogr Sci. 51(1):1-7. [CrossRef]
  8. 8. Tomar, A., Sharma, K., Chauhan, N. S., Mittal, A., & Bajaj, U. (2012). Formulation and Evaluation of Fast Dissolving Oral Film of Dicyclomine as potential route of Buccal Delivery “Formulation and Evaluation of Fast Dissolving Oral Film of Dicyclomine as potential route of Buccal Delivery” Int. J. Drug Dev. & Res, 4(2), 408–417. Retrieved from http://www.ijddr.in

Ayrıntılar

Birincil Dil

İngilizce

Konular

Eczacılık ve İlaç Bilimleri

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

20 Ocak 2023

Gönderilme Tarihi

29 Temmuz 2022

Kabul Tarihi

6 Ekim 2022

Yayımlandığı Sayı

Yıl 2023 Cilt: 47 Sayı: 1

Kaynak Göster

APA
Güneş, M., Turan, G., Dönmezer, A., Aydın Köse, F., Özer, K. Ö., & Karavana, S. Y. (2023). MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT. Journal of Faculty of Pharmacy of Ankara University, 47(1), 9-19. https://doi.org/10.33483/jfpau.1150792
AMA
1.Güneş M, Turan G, Dönmezer A, Aydın Köse F, Özer KÖ, Karavana SY. MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT. Ankara Ecz. Fak. Derg. 2023;47(1):9-19. doi:10.33483/jfpau.1150792
Chicago
Güneş, Meliha, Gökçe Turan, Armağan Dönmezer, Fadime Aydın Köse, Kevser Özgen Özer, ve Sinem Yaprak Karavana. 2023. “MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT”. Journal of Faculty of Pharmacy of Ankara University 47 (1): 9-19. https://doi.org/10.33483/jfpau.1150792.
EndNote
Güneş M, Turan G, Dönmezer A, Aydın Köse F, Özer KÖ, Karavana SY (01 Ocak 2023) MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT. Journal of Faculty of Pharmacy of Ankara University 47 1 9–19.
IEEE
[1]M. Güneş, G. Turan, A. Dönmezer, F. Aydın Köse, K. Ö. Özer, ve S. Y. Karavana, “MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT”, Ankara Ecz. Fak. Derg., c. 47, sy 1, ss. 9–19, Oca. 2023, doi: 10.33483/jfpau.1150792.
ISNAD
Güneş, Meliha - Turan, Gökçe - Dönmezer, Armağan - Aydın Köse, Fadime - Özer, Kevser Özgen - Karavana, Sinem Yaprak. “MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT”. Journal of Faculty of Pharmacy of Ankara University 47/1 (01 Ocak 2023): 9-19. https://doi.org/10.33483/jfpau.1150792.
JAMA
1.Güneş M, Turan G, Dönmezer A, Aydın Köse F, Özer KÖ, Karavana SY. MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT. Ankara Ecz. Fak. Derg. 2023;47:9–19.
MLA
Güneş, Meliha, vd. “MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT”. Journal of Faculty of Pharmacy of Ankara University, c. 47, sy 1, Ocak 2023, ss. 9-19, doi:10.33483/jfpau.1150792.
Vancouver
1.Meliha Güneş, Gökçe Turan, Armağan Dönmezer, Fadime Aydın Köse, Kevser Özgen Özer, Sinem Yaprak Karavana. MUCOADHESIVE ORODISPERSIBLE FILM FORMULATIONS OF RASAGILINE MESYLATE FOR PARKINSON TREATMENT. Ankara Ecz. Fak. Derg. 01 Ocak 2023;47(1):9-19. doi:10.33483/jfpau.1150792

Kapsam ve Amaç

Ankara Üniversitesi Eczacılık Fakültesi Dergisi, açık erişim, hakemli bir dergi olup Türkçe veya İngilizce olarak farmasötik bilimler alanındaki önemli gelişmeleri içeren orijinal araştırmalar, derlemeler ve kısa bildiriler için uluslararası bir yayım ortamıdır. Bilimsel toplantılarda sunulan bildiriler supleman özel sayısı olarak dergide yayımlanabilir. Ayrıca, tüm farmasötik alandaki gelecek ve önceki ulusal ve uluslararası bilimsel toplantılar ile sosyal aktiviteleri içerir.